Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease.

Patient with EMD or PMD at progression post-CAR T-cell therapy continued to show worse outcomes, with a median OS of 7.4 months (95% CI: 5.6-NA) compared to 21.1 months (95% CI: 10.6-NA) in those without, although this did not reach statistical significance (p=0.061) ( Figure 4E ).

also in 111,027 other papers